SEC Form 4 · accession 0001273351-26-000006
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward Carr
Officer — CHIEF ACCOUNTING OFFICER
Period of report
Sep 17, 2026
Accepted (ET)
Sep 18, 2026 · 4:36 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001690585
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 17, 2026 | M | 20,000 | $17.88 | A | 20,000 | D | |
| Common StockF2 | Sep 17, 2026 | S | 7,928 | $100.43 | D | 12,072 | D | |
| Common StockF3 | Sep 17, 2026 | S | 6,771 | $101.37 | D | 5,301 | D | |
| Common StockF4 | Sep 17, 2026 | S | 3,501 | $102.39 | D | 1,800 | D | |
| Common StockF5 | Sep 17, 2026 | S | 1,100 | $103.20 | D | 700 | D | |
| Common StockF6 | Sep 17, 2026 | S | 700 | $104.39 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $17.88 | Sep 17, 2026 | M | 20,000 | D | — | Jan 23, 2034 | Common Stock | 20,000 | 43,818 | D |
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2026.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.98 to $100.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.99 to $101.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.99 to $102.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.05 to $103.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.17 to $104.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F7The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.